Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Signaling Pathway of GP88 (Progranulin) in Breast Cancer Cells: Upregulation and Phosphorylation of c-myc by GP88/Progranulin in Her2-Overexpressing Breast Cancer Cells.

Kim WE, Yue B, Serrero G.

Breast Cancer (Auckl). 2016 May 5;9(Suppl 2):71-7. doi: 10.4137/BCBCR.S29371. eCollection 2015.

2.

A Dynamical Framework for the All-or-None G1/S Transition.

Barr AR, Heldt FS, Zhang T, Bakal C, Novák B.

Cell Syst. 2016 Jan 27;2(1):27-37. doi: 10.1016/j.cels.2016.01.001. Epub 2016 Jan 27.

3.

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It.

Luque-Cabal M, García-Teijido P, Fernández-Pérez Y, Sánchez-Lorenzo L, Palacio-Vázquez I.

Clin Med Insights Oncol. 2016 Mar 28;10(Suppl 1):21-30. doi: 10.4137/CMO.S34537. eCollection 2016. Review.

4.

Novel Molecular Markers for Breast Cancer.

Inoue K, Fry EA.

Biomark Cancer. 2016 Mar 13;8:25-42. doi: 10.4137/BIC.S38394. eCollection 2016. Review.

5.

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.

Duchnowska R, Wysocki PJ, Korski K, Czartoryska-Arłukowicz B, Niwińska A, Orlikowska M, Radecka B, Studziński M, Demlova R, Ziółkowska B, Merdalska M, Hajac Ł, Myśliwiec P, Zuziak D, Dębska-Szmich S, Lang I, Foszczyńska-Kłoda M, Karczmarek-Borowska B, Żawrocki A, Kowalczyk A, Biernat W, Jassem J; Central and East European Oncology Group (CEEOG).

Oncotarget. 2016 Jan 5;7(1):550-64. doi: 10.18632/oncotarget.6375.

7.

DEC1 regulates breast cancer cell proliferation by stabilizing cyclin E protein and delays the progression of cell cycle S phase.

Bi H, Li S, Qu X, Wang M, Bai X, Xu Z, Ao X, Jia Z, Jiang X, Yang Y, Wu H.

Cell Death Dis. 2015 Sep 24;6:e1891. doi: 10.1038/cddis.2015.247.

11.

Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.

Choudhary GS, Tat TT, Misra S, Hill BT, Smith MR, Almasan A, Mazumder S.

Oncotarget. 2015 Jul 10;6(19):16912-25.

12.

Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer.

Matsushita R, Seki N, Chiyomaru T, Inoguchi S, Ishihara T, Goto Y, Nishikawa R, Mataki H, Tatarano S, Itesako T, Nakagawa M, Enokida H.

Br J Cancer. 2015 Jul 14;113(2):282-9. doi: 10.1038/bjc.2015.195. Epub 2015 Jun 9.

PMID:
26057453
13.

Targeting cell cycle regulators in hematologic malignancies.

Aleem E, Arceci RJ.

Front Cell Dev Biol. 2015 Apr 9;3:16. doi: 10.3389/fcell.2015.00016. eCollection 2015. Review.

14.

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.

López-Knowles E, Wilkerson PM, Ribas R, Anderson H, Mackay A, Ghazoui Z, Rani A, Osin P, Nerurkar A, Renshaw L, Larionov A, Miller WR, Dixon JM, Reis-Filho JS, Dunbier AK, Martin LA, Dowsett M.

Breast Cancer Res. 2015 Mar 11;17:35. doi: 10.1186/s13058-015-0532-0.

16.

Up-regulation of cyclin E in breast cancer via estrogen receptor pathway.

Niu D, Wang G, Wang X.

Int J Clin Exp Med. 2015 Jan 15;8(1):910-5. eCollection 2015.

17.

The history and future of targeting cyclin-dependent kinases in cancer therapy.

Asghar U, Witkiewicz AK, Turner NC, Knudsen ES.

Nat Rev Drug Discov. 2015 Feb;14(2):130-46. doi: 10.1038/nrd4504. Review.

18.
19.

Reinforcing targeted therapeutics with phenotypic stability factors.

Yaswen P.

Cell Cycle. 2014;13(24):3818-22. doi: 10.4161/15384101.2014.985071.

20.

Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.

Kim J, Fox C, Peng S, Pusung M, Pectasides E, Matthee E, Hong YS, Do IG, Jang J, Thorner AR, Van Hummelen P, Rustgi AK, Wong KK, Zhou Z, Tang P, Kim KM, Lee J, Bass AJ.

J Clin Invest. 2014 Dec;124(12):5145-58. doi: 10.1172/JCI75200. Epub 2014 Nov 17.

Items per page

Supplemental Content

Write to the Help Desk